European Journal of Clinical Oncology

Welcome to the Journal

About the Journal

Cancer poses a major challenge to development; it undermines socio-economic advances throughout the world. It is estimated that the number of patients with cancer would increase from 12.7 million in the year 2008 to 22.2 million by 2030. It is universally agreed that the condition is reaching epidemic proportions. At this time, the European Journal of Clinical Oncology is conveniently placed in the scholarly communication milieu to help counter the menace of cancer by aiding the development of novel treatment strategies, by providing novel insights into the mechanisms underlying this complex disease. It is a well-known fact that, advances in care are enabling cancer patients to live longer, and lead better quality lives. With the enhancements in the knowledge of the aetiology of cancer, survival has improved substantially. In this setting, the European Journal of Clinical Oncology provides a high-profile platform to showcase major advances in cancer research.

Scope of the Journal

European Journal of Clinical Oncology strives to publish highest quality articles pertaining to clinical research, which are freely accessible to one and all. The scope of the journal encompasses topics Cancer Biology, prostate cancer, colorectal cancer, cancer immuno therapy, chemotherapy, cancer radiology, therapeutic cancer, cancer pathology.

Though original reports remain the primary focus of the journal, but this format of scientific communication is reinforced by appropriately selected commentaries, reviews, editorials, and other clinical work that relates to the care of cancer patients.

In order to create highly impactful and original content, the European Journal of Clinical Oncology has gathered an expert Editorial Board, comprising of illustrious scientists who ensure that each manuscript is fairly, but stringently peer-reviewed.

The team at the European Journal of Clinical Oncology takes immense pride in providing the authors with a streamlined and courteous publishing experience.

Fast Editorial Execution and Review Process (FEE-Review Process):
is participating in the Fast Editorial Execution and Review Process (FEE-Review Process) with an additional prepayment of $99 apart from the regular article processing fee. Fast Editorial Execution and Review Process is a special service for the article that enables it to get a faster response in the pre-review stage from the handling editor as well as a review from the reviewer. An author can get a faster response of pre-review maximum in 3 days since submission, and a review process by the reviewer maximum in 5 days, followed by revision/publication in 2 days. If the article gets notified for revision by the handling editor, then it will take another 5 days for external review by the previous reviewer or alternative reviewer.

Acceptance of manuscripts is driven entirely by handling editorial team considerations and independent peer-review, ensuring the highest standards are maintained no matter the route to regular peer-reviewed publication or a fast editorial review process. The handling editor and the article contributor are responsible for adhering to scientific standards. The article FEE-Review process of $99 will not be refunded even if the article is rejected or withdrawn for publication.

The corresponding author or institution/organization is responsible for making the manuscript FEE-Review Process payment. The additional FEE-Review Process payment covers the fast review processing and quick editorial decisions, and regular article publication covers the preparation in various formats for online publication, securing full-text inclusion in a number of permanent archives like HTML, XML, and PDF, and feeding to different indexing agencies.


Articles published in European Journal of Clinical Oncology have been cited by esteemed scholars and scientists all around the world. European Journal of Clinical Oncology has got h-index 8 , which means every article in European Journal of Clinical Oncology has got 8 average citations.

Editorial Board
  • Dr. Alireza Heidari, Ph.D., D.Sc.
    Director, Oncology, Radiation, LASER, Chemistry
    California South University (CSU), Irvine, California, USA., United States of America
    Additional Professor, Surgical Oncology
    AIIMS, India
  • Salah Boudjadi, MD, PhD
    Doctor, Molecular Pathology Section
    National Cancer Institute, Center for Cancer Research, Bethesda, USA
Journal Indexed in:
  • Google Scholar

Relevant Topics